XHKG
1477
Market cap517mUSD
Oct 09, Last price
5.08HKD
1D
0.59%
1Q
0.20%
IPO
-85.40%
Name
Ocumension Therapeutics
Chart & performance
P/E
—
P/S
4.33
EPS
—
Div yield, %
—
Shrs. gr., 5y
21.21%
Rev. gr., 5y
127.86%
Revenues
804m
+92.75%
Net income
-159m
L-40.80%
CFO
-105m
L-41.12%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in the People's Republic of China, Ocumension Therapeutics functions as a dedicated ophthalmic pharmaceutical platform. This company, along with its subsidiaries, is committed to the research, progression, and market introduction of therapeutic solutions for individuals with various eye conditions. Its extensive product offerings target treatments for disorders such as blepharitis, infectious and allergic conjunctivitis, dry eye syndrome, cataracts, glaucoma, ocular hypertension, post-surgical inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, corneal graft rejection, myopia, and optic neuritis. By December 31, 2021, Ocumension Therapeutics boasted a pipeline of 20 drug assets. The company, founded in 2017, maintains its headquarters in Suzhou, China.
Legal address
C/O The offices of Vistra (Cayman) Limited
P.O. Box 31119 Grand Pavilion
Hibiscus Way
802 West Bay Road, Grand Cayman
George Town KY1-1205
KY
P.O. Box 31119 Grand Pavilion
Hibiscus Way
802 West Bay Road, Grand Cayman
George Town KY1-1205
KY
Headquarters
尹中南路1858號
郭巷街道
吳中區
蘇州市, JS 215128
CN
郭巷街道
吳中區
蘇州市, JS 215128
CN
Address
No. 1858 Yinzhongnan Road
Guoxiang Subdistrict
Wuzhong District
Suzhou, JS 215128
CN
Guoxiang Subdistrict
Wuzhong District
Suzhou, JS 215128
CN
Previous name
Ocumension Limited
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||